How is dutasteride taken?
| Product | Strength | Pack |
|---|---|---|
| Avodart, US | 0.5 mg soft gelatin capsule1 | Bottles of 30 and 90 |
| Avodart, UK | 0.5 mg capsule2 | Blisters of 10 in containers of 10, 30, 50, 60 and 90 capsules |
| Zagallo, Japan (hair loss) | 0.1 mg and 0.5 mg capsules3 | Not in the pack |
| JALYN, US (combination) | 0.5 mg dutasteride with 0.4 mg tamsulosin hydrochloride4 | Bottles of 30 and 90 |
The US label gives one 0.5 mg capsule once daily for BPH, swallowed whole with or without food.1
Capsule strengths and what is supplied
The table is set at the top of the page
Dutasteride is labelled as a capsule taken by mouth, so nothing is mixed and no syringe volume applies.
Labelled dose and schedule
The US label gives the BPH dose as one 0.5 mg capsule once daily, and the combination dose as 0.5 mg dutasteride with tamsulosin 0.4 mg, each once daily.1 The UK SmPC also gives one 0.5 mg capsule taken orally once a day.2 The JALYN combination capsule is taken once daily about 30 minutes after the same meal.4
The US label gives a terminal elimination half-life of about 5 weeks at steady state, and says that following daily dosing, serum levels reach 65% of steady state after 1 month and about 90% after 3 months.1 The UK SmPC says an improvement may be seen early but a response can take up to 6 months.2
No label or fetched human trial covers dutasteride with testosterone or other steroids, and no label gives cycle dosing.
Hair loss, women and trial doses
The US label gives AVODART's use as the treatment of symptomatic BPH in men with an enlarged prostate and says it is not indicated for use in women, and the UK SmPC lists women, children and adolescents as contraindicated.12 Japan's review report records an androgenetic alopecia indication in men with a usual dose of 0.1 mg once daily, which may be increased to 0.5 mg.3 A review gives a different figure, saying Japan and South Korea have approved oral dutasteride 0.5 mg/d for male AGA.5
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Gubelin Harcha 20146 | Dutasteride 0.02, 0.1 or 0.5 mg a day; finasteride 1 mg a day; placebo | 917 men aged 20 to 50 with androgenetic alopecia, randomized | 24 weeks |
| Olsen 20067 | Dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily | Four hundred sixteen men with male pattern hair loss, randomized | 24 weeks |
| Japanese long-term study ARI1142643 | Dutasteride 0.5 mg once daily, open-label, no comparator | 120 Japanese men aged 20 to 50 with androgenetic alopecia | 52 weeks |
| CombAT, Roehrborn 20108 | Oral daily tamsulosin 0.4 mg, dutasteride 0.5 mg, or the combination | 4844 men aged 50 or over with BPH | 4 years |
| REDUCE, Andriole 20109 | Dutasteride 0.5 mg daily or placebo | Men aged 50 to 75; 6729 underwent a biopsy or prostate surgery (3305 dutasteride, 3424 placebo) | 4 years |
Storage and handling
The US label gives storage for the capsules as 25°C, with excursions to 15° to 30°C.1 The UK SmPC gives a shelf life of 4 years and says not to store above 30°C.2 The JALYN label adds that capsules may become deformed or discolored at high temperatures.4
The US label says dutasteride is absorbed through the skin, and women who are or could become pregnant are not to handle the capsules.1 The UK SmPC says to wash skin that touches a leaking capsule immediately with soap and water.2
Frequently asked questions
Is dutasteride labelled for women?
The US label says it is not indicated for use in women, and pharmacokinetics in women have not been studied.1
References
- Waylis Therapeutics (DailyMed). These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride) soft gelatin capsules Initial U.S. Approval: 2001. 2026. dailymed.nlm.nih.gov
- electronic Medicines Compendium (UK). Avodart 0.5mg soft capsules - Summary of Product Characteristics (SmPC) - print friendly - (emc). medicines.org.uk
- PMDA (Japan). Report on the Deliberation Results. pmda.go.jp
- Waylis Therapeutics (DailyMed). These highlights do not include all the information needed to use JALYN safely and effectively. See full prescribing information for JALYN. JALYN (dutasteride and tamsulosin hydrochloride) capsules Initial U.S. Approval: 2010. 2026. dailymed.nlm.nih.gov
- PubMed. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. 2022. pubmed.ncbi.nlm.nih.gov
- PubMed. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. 2014. pubmed.ncbi.nlm.nih.gov
- PubMed. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. 2006. pubmed.ncbi.nlm.nih.gov
- PubMed. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. 2010. pubmed.ncbi.nlm.nih.gov
- PubMed. Effect of dutasteride on the risk of prostate cancer. 2010. pubmed.ncbi.nlm.nih.gov